Ethical frameworks that support inclusion
While the exclusion of pregnant and lactating women from biomedical research has reduced pregnancy- and breastfeeding-specific risk in research contexts, it has not eliminated risk. Rather, it has shifted the burden of potential risk around drug safety from the clinical trial setting, where safety outcomes are carefully monitored, to the real-world clinical care setting, where safety outcomes are not systemically captured – with the effect of expanding the scope of harms experienced by this population. Harms include potential exposures to unacceptable risks for pregnant and lactating women, fetuses and infants, including incorrect dosing of drugs leading to either underdosing or toxicity, or limited access to indicated, preferred, or optimal treatments and preventives.
Ethical frameworks that attend to these harms support the inclusion of pregnant and lactating women in biomedical research, primarily as a matter of justice. The PHASES Working Group (2021) identified three ethical foundations that underpin the responsibility to address inequities in the evidence base for the use of medication in pregnancy and during the breastfeeding period.